AA
CRSP icon

ALPS Advisors’s CRISPR Therapeutics CRSP Stock Holding History

ALPS Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,581
Closed -$2.78M – 1038
2022
Q3 		$2.78M Sell
42,581
-3,369
-7% -$244K 0.03% 243
2022
Q2 		$2.79M Buy
+45,950
New +$2.7M 0.03% 251
2019
Q2 		– Sell
-125,116
Closed -$4.47M – 885
2019
Q1 		$4.47M Buy
125,116
+6,326
+5% +$219K 0.03% 177
2018
Q4 		$3.39M Buy
+118,790
New +$4.13M 0.03% 184

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ALPS Advisors's CRSP Position: Q4 2022 in Review

ALPS Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 42,581 shares — an estimated $2.78M sold.

ALPS Advisors first reported a position in CRSP in Q4 2018 and held it in 4 quarters. The position peaked at $4.47M in Q1 2019. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • ALPS Advisors reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 42,581 CRISPR Therapeutics shares in Q4 2022, an estimated $2.78M.
  • ALPS Advisors first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 4 quarters.
  • ALPS Advisors's CRISPR Therapeutics position peaked at $4.47M in Q1 2019.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.